Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myelofibrosis biology and contemporary management
Naseema Gangat, Ayalew Tefferi
British Journal of Haematology (2020) Vol. 191, Iss. 2, pp. 152-170
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Ayalew Tefferi
American Journal of Hematology (2020) Vol. 96, Iss. 1, pp. 145-162
Open Access | Times Cited: 257
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 2
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
Shivam Rai, Élodie Grockowiak, Nils Hansen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43
Defining disease modification in myelofibrosis in the era of targeted therapy
Naveen Pemmaraju, Srđan Verstovšek, Ruben A. Mesa, et al.
Cancer (2022) Vol. 128, Iss. 13, pp. 2420-2432
Open Access | Times Cited: 39
Single‐cell RNA sequencing reveals immune cell dysfunction in the peripheral blood of patients with highly aggressive gastric cancer
Rui Ma, Xuemeng Zhou, Xiaohui Zhai, et al.
Cell Proliferation (2024) Vol. 57, Iss. 5
Open Access | Times Cited: 12
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
Stephen T. Oh, Srđan Verstovšek, Vikas Gupta, et al.
eJHaem (2024) Vol. 5, Iss. 1, pp. 105-116
Open Access | Times Cited: 12
Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 5, pp. e383-e389
Closed Access | Times Cited: 6
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
Julian Grabek, Jasmin Straube, Megan J. Bywater, et al.
Cells (2020) Vol. 9, Iss. 8, pp. 1901-1901
Open Access | Times Cited: 37
Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
Ayalew Tefferi, Naseema Gangat, Animesh Pardanani, et al.
Cancer Research (2021) Vol. 82, Iss. 5, pp. 749-763
Open Access | Times Cited: 32
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
Giuseppe Gaetano Loscocco, Paola Guglielmelli
American Journal of Hematology (2025)
Open Access
GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms
Fuhui Li, Yudi Zhang, Chengwen Li, et al.
Pathology - Research and Practice (2025), pp. 155930-155930
Closed Access
Nocardia empyema in an immunocompromised host: A case report
Chantal Reyna, Evelyn Farias Luna, Ajay Sheshadri, et al.
Respiratory Medicine Case Reports (2025), pp. 102199-102199
Open Access
Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis
Olga Morath, Jenny Rinke, Andrew J. Walter, et al.
Annals of Hematology (2025)
Open Access
New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐XL/BCL‐2 inhibition with navitoclax
Naveen Pemmaraju, Jacqueline S. Garcia, Andrew C. Perkins, et al.
Cancer (2023) Vol. 129, Iss. 22, pp. 3535-3545
Open Access | Times Cited: 10
Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment
David Van Morckhoven, Nathan Dubois, Dominique Bron, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
The Genetic Architecture of High Bone Mass
Celia L. Gregson, Emma L. Duncan
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 25
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis
Lucia Longhitano, Daniele Tibullo, Nunzio Vicario, et al.
Aging (2020) Vol. 13, Iss. 23, pp. 25055-25071
Open Access | Times Cited: 25
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
David M. Ross, Jeffrey J. Babon, Denis Tvorogov, et al.
Haematologica (2021) Vol. 106, Iss. 5, pp. 1244-1253
Open Access | Times Cited: 21
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
Francesca Palandri, Mario Tiribelli, Massimo Breccia, et al.
Cancer (2021) Vol. 127, Iss. 15, pp. 2657-2665
Open Access | Times Cited: 21
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors
Andrea Duminuco, Calogero Vetro, Cesarina Giallongo, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 13, pp. 1449-1461
Closed Access | Times Cited: 7
miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype
Ernesto José Cuenca‐Zamora, Pedro Jesús Guijarro-Carrillo, María José López-Poveda, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 7, pp. 1326-1337
Closed Access | Times Cited: 2
Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review
Jiahao Song, Chanzi Huang, Lina Jia, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis
Jan Philipp Bewersdorf, Smith Giri, Rong Wang, et al.
Clinical Lymphoma Myeloma & Leukemia (2020) Vol. 20, Iss. 10, pp. e712-e723
Open Access | Times Cited: 16
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Jan Philipp Bewersdorf, Amar H. Sheth, Shaurey Vetsa, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 10, pp. 873.e1-873.e13
Open Access | Times Cited: 15
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
Christophe Willekens, Lucie Laplane, Tracy Dagher, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1287-1297
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top